Humanigen Inc(NASDAQ:HGEN) 
Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclona...
Website: https://www.humanigen.com/
Founded: 2000
CEO: Cameron Durrant
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-01-12
P
O 0.00
H 0.00
L 0.00
C 0.00
V 0
10EMA
20EMA
60EMA
120EMA
250EMA